Ibalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research.
CAS Number | 680188-33-4 |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[1] Hannah A Blair. Drugs. Ibalizumab: A Review in Multidrυg-Resistant HIV-1 Infection
[2] No authors listed. Ibalizumab
[3] No authors listed. Ibalizumab
[4] Robert L Bettiker, et al. Curr Opin HIV AIDS. Ibalizumab
[5] Anthony Markham. Drugs. Ibalizumab: First Global Approval
Related HIV Protease Products |
---|
Arg-Val-(Nle-p-nitro)-Phe-Glu-Ala-Nle-NH2
Arg-Val-(Nle-p-nitro)-Phe-Glu-Ala-Nle-NH2 is a fluorogenic substrate of HIV-1 protease. |
Ac-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2
Ac-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2 is a substrato peptídico of HIV-1 protease. |
HIV-1, HIV-2 Protease Substrate
HIV-1, HIV-2 Protease Substrate is the substrate of HIV-1, HIV-2 protease. |
HIV Protease Substrate IV
HIV Protease Substrate IV is a substrate of HIV protease. |
Herpes virus inhibitor 2
Herpes virus inhibitor 2 is a herpes virus inhibitor and disrupts herpes virus ribonucleotide reductase quaternary structure. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.